Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

[The relevance of biomarkers for personalised medicine].

Großhennig A, Benda N, Koch A.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1480-8. doi: 10.1007/s00103-013-1828-9. German.

PMID:
24084852
2.

[Personalised medicine. Aims and challenges].

Bieber T, Broich K.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1468-72. doi: 10.1007/s00103-013-1841-z. German.

PMID:
24170075
3.

[Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].

Müller-Berghaus J, Volkers P, Scherer J, Cichutek K.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1538-44. doi: 10.1007/s00103-013-1826-y. German.

PMID:
24170083
4.

The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.

Li M, Yu T, Hu YF.

Stat Med. 2015 Jun 30;34(14):2222-34. doi: 10.1002/sim.6476. Epub 2015 Mar 16.

PMID:
25779099
5.

[Personalised medicine in psychiatry and psychotherapy. A review of the current state-of-the-art in the biomarker-based early recognition of psychoses].

Koutsouleris N, Ruhrmann S, Falkai P, Maier W.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1522-30. doi: 10.1007/s00103-013-1840-0. Review. German.

PMID:
24170081
6.

Defining drug response for stratified medicine.

Lonergan M, Senn SJ, McNamee C, Daly AK, Sutton R, Hattersley A, Pearson E, Pirmohamed M.

Drug Discov Today. 2017 Jan;22(1):173-179. doi: 10.1016/j.drudis.2016.10.016. Epub 2016 Nov 3. Review.

PMID:
27818254
7.

Personalized medicine: Time for one-person trials.

Schork NJ.

Nature. 2015 Apr 30;520(7549):609-11. doi: 10.1038/520609a. No abstract available.

PMID:
25925459
8.

[Personalised medicine for the diagnosis and treatment of allergic diseases].

Vieths S, Bieber T.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1531-7. doi: 10.1007/s00103-013-1821-3. German.

PMID:
24170082
9.

Personalized medicine in children with asthma.

Pijnenburg MW, Szefler S.

Paediatr Respir Rev. 2015 Mar;16(2):101-7. doi: 10.1016/j.prrv.2014.10.003. Epub 2014 Nov 8. Review.

PMID:
25458797
10.

[Personalised medicine].

Broich K, Bieber T.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1465-7. doi: 10.1007/s00103-013-1843-x. German. No abstract available.

PMID:
24170074
11.

Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.

Schneider D, Bianchini G, Horgan D, Michiels S, Witjes W, Hills R, Plun-Favreau J, Brand A, Lawler M; EAPM Working Group for Oncology Clinical Research.

Public Health Genomics. 2015;18(6):349-58. doi: 10.1159/000441556. Epub 2015 Nov 11.

12.

Personalized Medicine: Genomics Trials in Oncology.

Hayes DF, Schott AF.

Trans Am Clin Climatol Assoc. 2015;126:133-43. Review.

13.

Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.

Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, Reardon DA.

Curr Oncol Rep. 2011 Feb;13(1):42-9. doi: 10.1007/s11912-010-0144-x. Review.

14.

[Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer].

Buettner R, Heydt C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1502-8. doi: 10.1007/s00103-013-1823-1. Review. German.

PMID:
24170079
15.

Biostatistic tools in pharmacogenomics--advances, challenges, potential.

Sato Y, Laird NM, Yoshida T.

Curr Pharm Des. 2010;16(20):2232-40. Review.

PMID:
20459388
16.

Genomics, personalized medicine, and supportive cancer care.

Sonis ST.

Am Soc Clin Oncol Educ Book. 2015:9-16. doi: 10.14694/EdBook_AM.2015.35.9. Review. No abstract available.

17.

Integrating biomarker information within trials to evaluate treatment mechanisms and efficacy for personalised medicine.

Dunn G, Emsley R, Liu H, Landau S.

Clin Trials. 2013 Oct;10(5):709-19. doi: 10.1177/1740774513499651. Epub 2013 Sep 2.

PMID:
24000376
18.

Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.

Blaus A, Madabushi R, Pacanowski M, Rose M, Schuck RN, Stockbridge N, Temple R, Unger EF.

Circulation. 2015 Oct 13;132(15):1425-32. doi: 10.1161/CIRCULATIONAHA.114.009761.

19.

[Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Stingl JC, Just KS, Kaumanns K, Schurig-Urbaniak M, Scholl C, von Mallek D, Brockmöller J.

Internist (Berl). 2016 Mar;57(3):289-97. doi: 10.1007/s00108-015-0013-7. Review. German.

PMID:
26830424
20.

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.

Hess GP, Fonseca E, Scott R, Fagerness J.

Genet Res (Camb). 2015 Jun 1;97:e13. doi: 10.1017/S0016672315000099. Review.

PMID:
26030725

Supplemental Content

Support Center